New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
11:32 EDTWUBA, QIWI, DB, KERX, SPRD, AZN, ARUN, NSR, PWRD, SHLDOptions with decreasing implied volatility:
Options with decreasing implied volatility: NSR KERX WUBA ARUN DB SHLD AZN QIWI PWRD SPLS
News For NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
13:43 EDTKERXKeryx mentioned cautiously in a Seeking Alpha Pro article
Subscribe for More Information
10:18 EDTSHLDSears Holdings volatility at low end of 44-month range as shares trend higher
Subscribe for More Information
10:08 EDTWUBAHigh option volume stocks
Subscribe for More Information
09:45 EDTAZNUBS to hold a field trip
Subscribe for More Information
09:06 EDTAZNInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
09:03 EDTAZNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:36 EDTAZNPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 22, 2015
18:14 EDTDBDeutsche Bank revamp to impact retail operations, Reuters says
The planned restructuring by Deutsche Bank will have the most impact on the bank's retail operations, says Reuters. According to sources, the bank's retail operations will "bear the brunt" of the revamp and will most likely be spun off in a stock market listing, added Reuters. Reference Link
17:51 EDTDBLawsky targets Deutsche Bank in Libor probe, FT says
According to people familiar with the matter, New York state's financial services regulator Benjamin Lawsky has joined other regulators investigating Deutsche Bank for manipulation of the Libor benchmark borrowing rate, says the Financial Times. Reference Link
March 20, 2015
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.
07:55 EDTAZNAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:17 EDTDBDeutsche Bank investors pushing for Postbank sale, Financial Times says
Subscribe for More Information
March 19, 2015
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
March 18, 2015
12:35 EDTSHLDSears supply chain under pressure, WSJ says
Subscribe for More Information
March 17, 2015
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
09:17 EDTWUBA58.com 2.5M share Block Trade priced at $44.10
The deal range was $43.90-$44.20. Credit Suisse acted as sole book running manager for the offering.
March 16, 2015
14:08 EDTDBEU regulator says time for fine-tuning, Reuters says
The Basel Committee on Banking Supervision believes the necessary bank regulatory framework is in place though some additional work must be done to finalize leverage ratio and capital floor rules, Reuters reported yesterday, citing statements by secretary-general William Coen at a financial conference in Doha. Coen added, "We're now at the state where we can take a step back and look to see how [the regulations] fit together," cautioning that further analysis must be data-driven but admitting that both banks and regulatory bodies were feeling "regulation fatigue." Publicly traded companies in the space include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), RBS (RBS) and UBS (UBS). Reference Link
10:07 EDTWUBAHigh option volume stocks
Subscribe for More Information
09:30 EDTDBConsortium wants to securitize $5.3B of debt from GE Capital, Reuters says
Subscribe for More Information
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use